Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
Kukulka, M., Nudurupati, S., Perez, M. C.Volume:
9
Language:
english
Journal:
Therapeutic Advances in Gastroenterology
DOI:
10.1177/1756283x16666800
Date:
November, 2016
File:
PDF, 591 KB
english, 2016